Blog
Bet on JNJ & Hold on to Apple to Grow Your Retirement Fund Stress-Free
In a well-balanced retirement portfolio, investors should aim for a mix of defensive and growth stocks. This approach offers both stability and the potential for wealth creation over time. By
2025: The Year of Crypto Access & Regulation
The Crypto Industry Proves Resilient
Cryptocurrencies and the digital asset market have come a long way since an anonymous person or person (s) dubbed “Satoshi Nakamoto” released the 2008 Bitcoin
Can Cannabis Stocks Reverse Their Prolonged Downtrend?
When Canada legalized recreational cannabis in 2018, many believed that the United States wouldn’t be far behind. Optimism grew further when the 2018 Farm Bill legalized hemp nationwide, fueling
Innodata's 375% EBITDA Jump Shows Operating Leverage: More to Come?
Innodata Inc. INOD delivered another standout quarter in the second quarter of 2025, with results underscoring its strong operating leverage and expanding role in the AI services ecosystem. Revenues
Consolidated Edison Q2 Earnings Beat Estimates, Revenues Rise Y/Y
Consolidated Edison, Inc. ED reported second-quarter 2025 adjusted earnings of 67 cents per share, which topped the Zacks Consensus Estimate of 66 cents by 1.5%. The bottom line also improved 13.6%
C3.ai's Generative AI Surge: A Catalyst for Fiscal 2026 Upside?
C3.ai, Inc. AI closed fiscal 2025 with strong momentum, positioning its Generative AI and agentic AI platforms as central growth drivers for fiscal 2026. The company reported fiscal fourth-quarter
BBAI Pre-Q2 Preview: Tracking AI Adoption & Federal Contract Momentum
BigBear.ai Holdings, Inc. BBAI is set to report second-quarter 2025 results on Aug. 11, with rising AI adoption and expanding federal contract momentum likely to be key performance drivers.
AI
BitFuFu Inc. (FUFU) Earnings Expected to Grow: Should You Buy?
BitFuFu Inc. (FUFU) is expected to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended June 2025. This widely-known consensus outlook gives
Analysts Estimate Flowers Foods (FLO) to Report a Decline in Earnings: What to Look Out for
Wall Street expects a year-over-year decline in earnings on higher revenues when Flowers Foods (FLO) reports results for the quarter ended June 2025. While this widely-known consensus outlook is
SurModics (SRDX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
For the quarter ended June 2025, SurModics (SRDX) reported revenue of $29.57 million, down 2.6% over the same period last year. EPS came in at $0.06, compared to -$0.27 in the year-ago quarter.
The
5 Stocks in QQQ ETF That Drove Nasdaq's Record Closing High
The Nasdaq Composite closed at a record high on Aug. 7, even though new tariffs on imports from dozens of countries were implemented. With this, the index has posted 17 all-time closing highs in
Best Momentum Stock to Buy for August 8th
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, August 8th:
Rigel Pharmaceuticals RIGL:This clinical-stage drug development company that
Wall Street Analysts Believe Genmab (GMAB) Could Rally 33.8%: Here's is How to Trade
Shares of Genmab A/S Sponsored ADR (GMAB) have gained 3.8% over the past four weeks to close the last trading session at $22.69, but there could still be a solid upside left in the stock if
How Much Upside is Left in Tidewater (TDW)? Wall Street Analysts Think 31.5%
Tidewater (TDW) closed the last trading session at $56.88, gaining 7.3% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street
How Much Upside is Left in Hesai Group Sponsored ADR (HSAI)? Wall Street Analysts Think 27.28%
Hesai Group Sponsored ADR (HSAI) closed the last trading session at $22.29, gaining 1.3% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets
Can InfuSystems Holdings (INFU) Climb 79.52% to Reach the Level Wall Street Analysts Expect?
InfuSystems Holdings, Inc. (INFU) closed the last trading session at $7.52, gaining 21.5% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets
Wall Street Analysts See a 32.98% Upside in Great Lakes Dredge & Dock (GLDD): Can the Stock Really Move This High?
Great Lakes Dredge & Dock (GLDD) closed the last trading session at $11.28, gaining 0.8% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets
Wall Street Analysts Think Contineum Therapeutics, Inc. (CTNM) Could Surge 235.81%: Read This Before Placing a Bet
Contineum Therapeutics, Inc. (CTNM) closed the last trading session at $6.73, gaining 67% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets
Wall Street Analysts See a 55.87% Upside in Superior Group (SGC): Can the Stock Really Move This High?
Shares of Superior Group (SGC) have gained 2.7% over the past four weeks to close the last trading session at $11.42, but there could still be a solid upside left in the stock if short-term price
Wall Street Analysts Believe Sky Harbour Group (SKYH) Could Rally 72.97%: Here's is How to Trade
Sky Harbour Group Corporation (SKYH) closed the last trading session at $10.36, gaining 1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets
Here's Why Foghorn Therapeutics (FHTX) Looks Ripe for Bottom Fishing
Shares of Foghorn Therapeutics Inc. (FHTX) have been struggling lately and have lost 5.1% over the past week. However, a hammer chart pattern was formed in its last trading session, which could mean
Reddit Inc. (RDDT) Just Flashed Golden Cross Signal: Do You Buy?
After reaching an important support level, Reddit Inc. (RDDT) could be a good stock pick from a technical perspective. RDDT recently experienced a "golden cross" event, which saw its 50-day simple
Does Remitly Global (RELY) Have the Potential to Rally 43.06% as Wall Street Analysts Expect?
Remitly Global, Inc. (RELY) closed the last trading session at $18.95, gaining 3.7% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by
After Golden Cross, Halozyme Therapeutics (HALO)'s Technical Outlook is Bright
Halozyme Therapeutics, Inc. (HALO) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, HALO's 50-day simple moving average



